Investigating how ERK1/2 signaling affects immune response and lung damage from SARS-CoV-2.
Official title: Role of ERK1/2 signaling in SARS-CoV-2 -induced dysregulated immunity and lung pathology.
Funded at Oklahoma State University Stillwater · NIH-10812076 · Data updated 2026-11-12
This study is looking at how a specific signaling pathway in our immune cells affects lung damage and inflammation in people with severe COVID-19, and it hopes to find ways to reduce harmful inflammation while boosting the body's ability to fight the virus, which could help patients with serious lung issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma State University Stillwater NIH-funded |
| Lab location | 1 site (Stillwater, United States) |
| Project start | September 6, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $408,606 |
| NIH project number | 1R01HL165423-01A1 |
| Project ID | NIH-10812076 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing severe respiratory symptoms or complications related to COVID-19.
✕Less likely to help
Patients with mild COVID-19 symptoms or those not affected by respiratory issues may not benefit from this research.
What this research studies
This research focuses on understanding how the ERK1/2 signaling pathway influences the immune response and lung damage caused by the SARS-CoV-2 virus. By examining the role of myeloid cells and their signaling mechanisms, the study aims to identify how these cells contribute to excessive inflammation and impaired antiviral responses during COVID-19. The researchers will explore the potential of blocking ERK1/2 activity to reduce harmful inflammation while enhancing the body's ability to fight the virus. This could lead to new therapeutic strategies for patients suffering from severe lung complications due to COVID-19.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients with severe COVID-19-related lung injuries.
How similar studies have gone: Other research has shown promising results in targeting similar pathways for treating viral-induced lung injuries, indicating potential for success in this approach.
Where this research is happening
-
Oklahoma State University Stillwater
Stillwater, United States Active
Researchers
- Principal investigator: Channappanavar, Rudragouda — Oklahoma State University Stillwater
- Study coordinator: Channappanavar, Rudragouda
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.